Akiko Morimoto1, Yukako Tatsumi2, Nao Sonoda3, Naomi Miyamatsu1, Tetsuo Shimoda4, Shiro Sakaguchi4. 1. 1Department of Clinical Nursing, Shiga University of Medical Science, Tsukinowa-cho Seta, Otsu, Shiga 520-2192 Japan. 2. 2Department of Hygiene and Public Health, Teikyo University, 2-11-1 Kaga, Itabashi-Ku, Tokyo 173-8605 Japan. 3. 3Department of Mathematical Health Science, Graduate School of Medicine, Osaka University, 1-7 Yamadaoka, Suita, Osaka 565-0871 Japan. 4. 4Saku Central Hospital, 197 Usuda, Saku, Nagano 384-0301 Japan.
Abstract
AIMS: To assess the impact of metabolic syndrome (MetS) on the incidence of type 2 diabetes in middle-aged Japanese individuals with impaired insulin secretion (IIS). METHODS: This cohort study included 1,702 individuals aged 40-59 without diabetes at baseline who underwent a comprehensive medical check-up between April 2008 and March 2009 at Saku Central Hospital. Participants were classified according to their IIS and insulin resistance (IR) status [normal, isolated IR (i-IR), or isolated IIS (i-IIS)] and MetS (presence or absence). They were followed up until March 2014. Type 2 diabetes was defined based on fasting and 2-h post-load plasma glucose concentrations and by the receipt of medical treatment for diabetes. RESULTS: During 7,572 person-years of follow-up, 92 individuals developed type 2 diabetes. The incidence rates (/1,000 person-years) for type 2 diabetes in the normal without MetS, normal with MetS, i-IR without MetS, i-IR with MetS, i-IIS without MetS, and i-IIS with MetS groups were 5.3, 3.7, 11.3, 24.7, 16.7, and 59.5, respectively. The multivariable-adjusted hazard ratios (HRs) and 95 % confidence intervals (CIs) for type 2 diabetes in the normal with MetS, i-IR with MetS, and i-IIS with MetS groups, relative to the normal without MetS group, were 0.52 (0.12-2.25), 3.78 (1.93-7.42), and 7.94 (3.96-15.91), respectively. Additionally, a positive association of MetS with type 2 diabetes was observed in the i-IIS group [HR (95 % CI) 3.56 (1.88-6.73)] but not in the normal and i-IR groups. CONCLUSIONS: The prevention of MetS is important, particularly in individuals with low insulin secretion.
AIMS: To assess the impact of metabolic syndrome (MetS) on the incidence of type 2 diabetes in middle-aged Japanese individuals with impaired insulin secretion (IIS). METHODS: This cohort study included 1,702 individuals aged 40-59 without diabetes at baseline who underwent a comprehensive medical check-up between April 2008 and March 2009 at Saku Central Hospital. Participants were classified according to their IIS and insulin resistance (IR) status [normal, isolated IR (i-IR), or isolated IIS (i-IIS)] and MetS (presence or absence). They were followed up until March 2014. Type 2 diabetes was defined based on fasting and 2-h post-load plasma glucose concentrations and by the receipt of medical treatment for diabetes. RESULTS: During 7,572 person-years of follow-up, 92 individuals developed type 2 diabetes. The incidence rates (/1,000 person-years) for type 2 diabetes in the normal without MetS, normal with MetS, i-IR without MetS, i-IR with MetS, i-IIS without MetS, and i-IIS with MetS groups were 5.3, 3.7, 11.3, 24.7, 16.7, and 59.5, respectively. The multivariable-adjusted hazard ratios (HRs) and 95 % confidence intervals (CIs) for type 2 diabetes in the normal with MetS, i-IR with MetS, and i-IIS with MetS groups, relative to the normal without MetS group, were 0.52 (0.12-2.25), 3.78 (1.93-7.42), and 7.94 (3.96-15.91), respectively. Additionally, a positive association of MetS with type 2 diabetes was observed in the i-IIS group [HR (95 % CI) 3.56 (1.88-6.73)] but not in the normal and i-IR groups. CONCLUSIONS: The prevention of MetS is important, particularly in individuals with low insulin secretion.
Authors: Juliana C N Chan; Vasanti Malik; Weiping Jia; Takashi Kadowaki; Chittaranjan S Yajnik; Kun-Ho Yoon; Frank B Hu Journal: JAMA Date: 2009-05-27 Impact factor: 56.272
Authors: Trevor J Orchard; Marinella Temprosa; Ronald Goldberg; Steven Haffner; Robert Ratner; Santica Marcovina; Sarah Fowler Journal: Ann Intern Med Date: 2005-04-19 Impact factor: 25.391
Authors: Naveed Sattar; Alex McConnachie; A Gerald Shaper; Gerard J Blauw; Brendan M Buckley; Anton J de Craen; Ian Ford; Nita G Forouhi; Dilys J Freeman; J Wouter Jukema; Lucy Lennon; Peter W Macfarlane; Michael B Murphy; Chris J Packard; David J Stott; Rudi G Westendorp; Peter H Whincup; James Shepherd; S Goya Wannamethee Journal: Lancet Date: 2008-05-22 Impact factor: 79.321
Authors: Pirjo Ilanne-Parikka; Johan G Eriksson; Jaana Lindström; Markku Peltonen; Sirkka Aunola; Helena Hämäläinen; Sirkka Keinänen-Kiukaanniemi; Mauri Laakso; Timo T Valle; Jorma Lahtela; Matti Uusitupa; Jaakko Tuomilehto Journal: Diabetes Care Date: 2008-01-09 Impact factor: 19.112